Kyntra Bio Advances Prostate Cancer Drug, Submits Roxadustat Protocol to FDA
Event summary
- Phase 2 monotherapy trial of FG-3246 for mCRPC on track for interim analysis in 2H 2026.
- Positive combination trial results with enzalutamide presented at ASCO GU 2026.
- Submitted Phase 3 protocol for roxadustat in LR-MDS to FDA, aiming for trial start in 2H 2026.
- $109.4M in cash provides runway into 2028.
The big picture
Kyntra Bio is advancing its pipeline with two key programs: FG-3246, a first-in-class ADC for prostate cancer, and roxadustat for anemia in LR-MDS. The company's strategic focus on oncology and rare diseases aligns with growing demand for targeted therapies, though its financials reflect the high burn rate typical of biotech development stages. The submission of the roxadustat Phase 3 protocol marks a critical step in expanding its commercial footprint beyond oncology.
What we're watching
- Clinical Validation
- Whether FG-3246's interim Phase 2 results will validate its monotherapy approach in mCRPC.
- Regulatory Timing
- The pace at which FDA will review and approve the roxadustat Phase 3 protocol.
- Cash Management
- How Kyntra Bio will allocate its $109.4M cash runway to balance R&D and potential partnerships.
Related topics